INCIDENCE OF SKELETAL COMPLICATIONS IN PATIENTS WITH BONE METASTATIC PROSTATE CANCER AND HORMONE REFRACTORY DISEASE: PREDICTIVE ROLE OF BONE RESORPTION AND FORMATION MARKERS EVALUATED AT BASELINE
The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
PURPOSE: We evaluated the incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease. We also assessed the predictive role of bone turnover markers determined at baseline. MATERIALS AND METHODS: A total of 112 patients were consecutively enrolled in our study from July 1990 to July 1998 and followed until death or the last followup. Bone pain, disease extent in bone, serum prostate specific antigen, hemoglobin, and a panel of bone formation and resorption markers were assessed at baseline before any second line treatment. RESULTS: Skeletal complications in 34 patients (30.3%, estimated yearly incidence 12.3%) involved vertebral deformity or collapse requiring spinal orthosis in 20 (17.9%), spinal cord compression in 7 (6.2%), pathological bone fracture in 10 (8.9%), symptomatic hypercalcemia in 1 (0.9%) and symptomatic hypocalcemia in 1 (0.9%). Median time to the evidence of the initial skeletal complication was 9.5 months. These adverse events did not influence overall survival. At baseline patients with eventual skeletal complications had greater bone pain (p = 0.02), a heavier tumor load in bone (p = 0.005), lower performance status (p = 0.05), and higher serum alkaline phosphatase (p <0.02) and urinary deoxypyridoline (p <0.05) than their counterparts. Multivariate analysis revealed that only urinary deoxypyridinoline was independently associated with the onset of these events (p <0.02). The scatterplot of urinary deoxypyridinoline values in patients with and without skeletal complications enabled us to detect a cutoff of 38 pM./mM. for predicting 51% of skeletal events with only an 8% false-positive rate. CONCLUSIONS: Skeletal complications are common in patients with prostate cancer and hormone refractory disease. Bone loss is the major cause of onset. Baseline deoxypyridinoline at the cutoff point noted had moderate sensitivity but high specificity for predicting these adverse skeletal events.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A common complication of prostate cancer is metastasis to the bone tissue, which occurs in about 10% of patients with primary disease and 80% of patients with advanced, late-stage disease (Berruti et al., 2000; Bubendorf et al., 2000).”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Berruti et al., 2000
Citations
Cites
Nonparametric Statistics for the Behavioral Sciences
Guitton, H., & Siegel, S. (1958) · Revue économique · doi:10.2307/3498751 · Cited by 35,245
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
Skeletal complications of malignancy
Coleman, R. E. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19971015)80:8+<1588::aid-cncr9>3.0.co;2-g · Cited by 1,502
A computer program for comparing K samples with right-censored data
Lee, E. T., & Desu, M. M. (1972) · Computer Programs in Biomedicine · doi:10.1016/0010-468x(72)90019-0 · Cited by 705
Hanson, D. A., Weis, M. A. E., Bollen, A.-M., Maslan, S. L., Singer, F. R., & Dr. Eyre, D. R. (1992) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650071119 · Cited by 656
Risteli, J., Elomaa, I., Niemi, S., Novamo, A., & Risteli, L. (1993) · Clinical Chemistry · doi:10.1093/clinchem/39.4.635 · Cited by 622
Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen
Melkko, J., Niemi, S., Risteli, L., & Risteli, J. (1990) · Clinical Chemistry · doi:10.1093/clinchem/36.7.1328 · Cited by 513
Guise, T. A., & Mundy, G. R. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.1.0323 · Cited by 472
Molecular aspects of tumor cell invasion and metastasis
Aznavoorian, S. A., Murphy, A. N., Stetler‐Stevenson, W. G., & Liotta, L. A. (1993) · Cancer · doi:10.1002/1097-0142(19930215)71:4<1309::aid-cncr2820710423>3.0.co;2-m · Cited by 459
PROGRESSIVE OSTEOPOROSIS DURING ANDROGEN DEPRIVATION THERAPY FOR PROSTATE CANCER
DANIELL, H. W., DUNN, S. R., FERGUSON, D. W., LOMAS, G., NIAZI, Z., & STRATTE, P. T. (2000) · Journal of Urology · doi:10.1016/s0022-5347(05)68000-7 · Cited by 452
Cited by
Saad, F., Gleason, D. M., Murray, R., Tchekmedyian, S., Venner, P., Lacombe, L., Chin, J. L., Vinholes, J. J., Goas, J. A., & Chen, B. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.19.1458 · Cited by 1,656
“Patients with hormone-refractory metastatic prostate cancer are particularly prone to incapacitating progressive bone disease ( 10 ).”
BackgroundCornford, P., van den Bergh, R. C. N., Briers, E., Van den Broeck, T., Cumberbatch, M. G., De Santis, M., Fanti, S., Fossati, N., Gandaglia, G., Gillessen, S., et al. (2021) · European Urology · doi:10.1016/j.eururo.2020.09.046 · Cited by 1,079
“Direct symptoms from advanced or metastatic cancer, for example, pain, hypercalcaemia, spinal cord compression, and pathological fractures, also affect health adversely [173,174].”
BackgroundLevitt, D., & Levitt, M. (2016) · International Journal of General Medicine · doi:10.2147/ijgm.s102819 · Cited by 763
Coleman, R. E., Major, P., Lipton, A., Brown, J. E., Lee, K.-A., Smith, M., Saad, F., Zheng, M., Hei, Y. J., Seaman, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.091 · Cited by 533
Weinfurt, K. P., Li, Y., Castel, L. D., Saad, F., Timbie, J. W., Glendenning, G. A., & Schulman, K. A. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi122 · Cited by 362
Metadata
- Authors
- BERRUTI, A., DOGLIOTTI, L., BITOSSI, R., FASOLIS, G., GORZEGNO, G., BELLINA, M., TORTA, M., PORPIGLIA, F., FONTANA, D., & ANGELI, A.
- Affiliations
- Ospedale San Luigi Gonzaga (IT)
- Venue
- Journal of Urology
- Published
- 2000-10
- Volume
- 164
- Issue
- 4
- Pages
- 1248-1253
- ISSN
- 0022-5347 (ISSN-L)
- 1527-3792
- OpenAlex
- W2159622173
- Cited by
- 212
- References
- 33
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 5 · 2023: 5 · 2022: 5 · 2021: 6 · 2020: 3 · 2019: 4 · 2018: 4 · 2017: 2 · 2016: 6 · 2015: 8 · 2014: 9 · 2013: 8 · 2012: 10
- FWCI
- 6.31
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Journal of Urology (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Surgery › Management of metastatic bone disease
- Keywords
- skeletal complications, bone metastatic prostate cancer, castration-resistant prostate cancer, bone turnover markers, urinary deoxypyridinoline, bone resorption, bone formation, pathological fracture, spinal cord compression, vertebral collapse, alkaline phosphatase, predictive biomarkers, bone pain
- MeSH terms
- Aged, Aged, 80 and over, Alkaline Phosphatase, Amino Acids, Bone Neoplasms, Bone Resorption, Calcium, Evaluation Studies as Topic, Humans, Male, Middle Aged, Prostatic Neoplasms, Regression Analysis, Biomarkers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: INCIDENCE OF SKELETAL COMPLICATIONS IN PATIENTS WITH BONE METASTATIC PROSTATE CANCER AND HORMONE REFRACTORY DISEASE: PREDICTIVE ROLE OF BONE RESORPTION AND FORMATION MARKERS EVALUATED AT BASELINE. https://app.cochat.ai/papers/10.1016/s0022-5347(05)67149-2
- The paper
- BERRUTI, A., DOGLIOTTI, L., BITOSSI, R., FASOLIS, G., GORZEGNO, G., BELLINA, M., TORTA, M., PORPIGLIA, F., FONTANA, D., & ANGELI, A. (2000). INCIDENCE OF SKELETAL COMPLICATIONS IN PATIENTS WITH BONE METASTATIC PROSTATE CANCER AND HORMONE REFRACTORY DISEASE: PREDICTIVE ROLE OF BONE RESORPTION AND FORMATION MARKERS EVALUATED AT BASELINE. Journal of Urology. https://doi.org/10.1016/s0022-5347(05)67149-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.